Gregory S Thill

US Patent:

51027895, Apr 7, 1992

Filed:

Mar 15, 1989

Appl. No.:

7/323964

Inventors:

Robert S. Siegel - San Diego CA
Richard G. Buckholz - Encinitas CA
Gregory P. Thill - San Diego CA
Lillian M. Wondrack - San Diego CA

Assignee:

The Salk Institute Biotechnology/Industrial Associates, Inc. - San Diego CA

International Classification:

C07H 1512
C12P 2100
C12P 2102

US Classification:

435 694

Abstract:

Epidermal Growth Factor (EGF) is produced by recombinant DNA technology in Pichia pastoris yeast cells.

US Patent:

57078289, Jan 13, 1998

Filed:

May 3, 1995

Appl. No.:

8/433037

Inventors:

Juerg F. Tschopp - San Diego CA
Gregory P. Thill - San Diego CA
Russell A. Brierley - San Diego CA
Kathryn A. Barr - Bartlesville OK

Assignee:

Research Corporation Technologies, Inc. - Tucson AZ

International Classification:

C12P 2106
C12N 119
C12N 1500
C12N 1563

US Classification:

435 691

Abstract:

The present invention is directed to expression cassettes comprising a 5' regulatory region from at least one of the Pichia pastoris AOXI gene, p40 gene, DASI gene or HIS4 gene, operably linked to an HSA structural gene including the HSA signal sequence. The HSA structural gene has a translational start codon within 0 to 11 deoxyribonucleotides from the 5' end of the HSA structural gene and is operably linked to a 3' termination sequence. Further, the adenine and thymine content of the intervening deoxyribonucleotides is in the range from about 55 to about 64%. The expression cassette may be an autonomously replicating vector or an integrative vector. Other embodiments of the present invention include Pichia pastoris strains transformed with the HSA expression cassettes and processes for secretion of HSA using the expression cassettes.

US Patent:

56706308, Sep 23, 1997

Filed:

Jun 6, 1995

Appl. No.:

8/467345

Inventors:

Gregory P. Thill - San Diego CA

Assignee:

Research Corporation Technologies, Inc. - Tucson AZ

International Classification:

C07K 1410
C12N 1581

US Classification:

530403

Abstract:

A process for the enhanced production of antigenic particles consisting essentially of hepatitis B S protein and preS. sub. 2 protein. Also disclosed are novel DNA molecules and hosts transformed with these molecules.

US Patent:

56502966, Jul 22, 1997

Filed:

Jun 6, 1995

Appl. No.:

8/467660

Inventors:

Gregory P. Thill - San Diego CA

Assignee:

Research Corporation Technologies, Inc. - Tucson AZ

International Classification:

C12N 119
C12N 1551
C12N 1581

US Classification:

435 693

Abstract:

A process for the enhanced production of antigenic particles consisting essentially of hepatitis B S protein and preS. sub. 2 protein. Also disclosed are novel DNA molecules and hosts transformed with these molecules.